Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

1.115 -0.085 (-7.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,803,533
Open 1.170
Bid (Size) 1.110 (96)
Ask (Size) 1.120 (10)
Prev. Close 1.200
Today's Range 1.050 - 1.180
52wk Range 0.3258 - 1.530
Shares Outstanding 46,166,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent... 
Via FinancialNewsMedia

Performance

YTD
+19.9%
+19.9%
1 Month
+161.1%
+161.1%
3 Month
+123.0%
+123.0%
6 Month
+28.2%
+28.2%
1 Year
+9.3%
+9.3%

More News

Read More
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
Via FinancialNewsMedia
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Via FinancialNewsMedia
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Via FinancialNewsMedia
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Via FinancialNewsMedia
Topics Artificial Intelligence
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
Via FinancialNewsMedia
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For May 14, 2025
Via Benzinga
A Look at Oncolytics Biotech's Upcoming Earnings Report
Via Benzinga
What's going on in today's pre-market session
Via Chartmill
Earnings Scheduled For March 7, 2025
Via Benzinga
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Via FinancialNewsMedia
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Via FinancialNewsMedia
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Via FinancialNewsMedia
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Via FinancialNewsMedia
Topics Death
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Via FinancialNewsMedia
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Via FinancialNewsMedia
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
Via FinancialNewsMedia
Topics Artificial Intelligence
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Shares publicly traded?
Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
Oncolytics Biotech Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONCY on the Nasdaq Stock Market
What is the current price of Oncolytics Biotech Inc. - Common Shares?
The current price of Oncolytics Biotech Inc. - Common Shares is 1.115
When was Oncolytics Biotech Inc. - Common Shares last traded?
The last trade of Oncolytics Biotech Inc. - Common Shares was at 07/10/25 04:00 PM ET
What is the market capitalization of Oncolytics Biotech Inc. - Common Shares?
The market capitalization of Oncolytics Biotech Inc. - Common Shares is 51.48M
How many shares of Oncolytics Biotech Inc. - Common Shares are outstanding?
Oncolytics Biotech Inc. - Common Shares has 51M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.